## Maximino Redondo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/267556/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Use of health services among long-term breast cancer survivors in Spain: longitudinal study based on real-world data. Journal of Cancer Survivorship, 2022, 16, 132-141.	2.9	1
2	Influence of Diagnostic Delay on Survival Rates for Patients with Colorectal Cancer. International Journal of Environmental Research and Public Health, 2022, 19, 3626.	2.6	6
3	Adherence of long-term breast cancer survivors to follow-up care guidelines: a study based on real-world data from the SURBCAN cohort. Breast Cancer Research and Treatment, 2022, 193, 455-465.	2.5	3
4	Impact of Detection Mode in a Large Cohort of Women Taking Part in a Breast Screening Program. The Journal of Breast Health, 2022, 18, 182-189.	1.0	2
5	Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance. Cancers, 2022, 14, 2255.	3.7	11
6	Factors that Influence Treatment Delay for Patients with Breast Cancer. Annals of Surgical Oncology, 2021, 28, 3714-3721.	1.5	13
7	Multimorbidity clusters among longâ€ŧerm breast cancer survivors in Spain: Results of the <scp>SURBCAN</scp> study. International Journal of Cancer, 2021, 149, 1755-1767.	5.1	10
8	Effect of Breast Cancer Treatment on Dietary Vitamin Intake Levels. International Journal of Environmental Research and Public Health, 2021, 18, 19.	2.6	3
9	ASO Author Reflections: Predictive Factors for Surgical Treatment Delay in Localised Breast Cancer. Annals of Surgical Oncology, 2021, 28, 3722.	1.5	1
10	Stage- and age-adjusted cost-effectiveness analysis of laparoscopic surgery in rectal cancer. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 1167-1176.	2.4	2
11	Predictors of readmission and reoperation in patients with colorectal cancer. Supportive Care in Cancer, 2020, 28, 2339-2350.	2.2	9
12	Reply to: Characteristics in patients with symptomatic colorectal carcinomas and those detected by screening'. European Journal of Surgical Oncology, 2020, 46, 221.	1.0	0
13	Type and Consequences of Short-Term Complications in Colon Cancer Surgery, Focusing on the Oldest Old. Clinical Colorectal Cancer, 2020, 19, e18-e25.	2.3	5
14	Use of real-world data to study health services utilisation and comorbidities in long-term breast cancer survivors (the SURBCAN study): study protocol for a longitudinal population-based cohort study. BMJ Open, 2020, 10, e040253.	1.9	7
15	Factors associated with colon cancer early, intermediate and late recurrence after surgery for stage I–III: A 5â€year prospective study. European Journal of Cancer Care, 2020, 29, e13317.	1.5	2
16	Relationship between glycemic control and chronic obstructive pulmonary disease in patients with type 2 diabetes: A nested case-control study. Primary Care Diabetes, 2020, 14, 729-735.	1.8	4
17	Analysis of the association between adverse events and outcome in patients receiving a programmed death ligand-1 antibody. Chinese Clinical Oncology, 2020, 9, 57-57. 	1.2	1
18	Impact of adjuvant chemotherapy on the survival of patients with breast cancer diagnosed by screening. Cancer Medicine. 2019. 8. 6662-6670.	2.8	3

#	Article	IF	CITATIONS
19	Biological and prognostic differences between symptomatic colorectal carcinomas and those detected by screening. European Journal of Surgical Oncology, 2019, 45, 1876-1881.	1.0	5
20	Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 2296.	4.1	35
21	Clinical–pathological characteristics and short-term follow-up associated with proliferation, apoptosis and angiogenesis in a prospective cohort of patients with colorectal tumours. Tumor Biology, 2019, 41, 101042831983568.	1.8	2
22	Targeting Receptor Kinases in Colorectal Cancer. Cancers, 2019, 11, 433.	3.7	48
23	Risk factors affecting hospital stay among patients undergoing colon cancer surgery: a prospective cohort study. Supportive Care in Cancer, 2019, 27, 4133-4144.	2.2	6
24	Immunotherapy: A Challenge of Breast Cancer Treatment. Cancers, 2019, 11, 1822.	3.7	106
25	Clinical and sociodemographic factors that may influence the resilience of women surviving breast cancer: cross-sectional study. Supportive Care in Cancer, 2019, 27, 1279-1286.	2.2	15
26	Regulation of Clusterin Gene Expression. Current Protein and Peptide Science, 2018, 19, 612-622.	1.4	19
27	Expression and Prognostic Value of Oestrogen Receptor Beta in Colorectal Cancer. Pathology and Oncology Research, 2018, 24, 871-879.	1.9	4
28	Outcomes of open versus laparoscopic surgery in patients with rectal cancer. International Journal of Colorectal Disease, 2018, 33, 99-103.	2.2	7
29	Factors Associated with Prolonged Patient-Attributable Delay in the Diagnosis of Colorectal Cancer. Cancer Research and Treatment, 2018, 50, 1270-1280.	3.0	12
30	Free Thyroxine Determination in the Emergency Department Is a Predictor of Acute Pancreatitis Evolution. Pancreas, 2018, 47, 1322-1327.	1.1	9
31	Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy. International Journal of Molecular Sciences, 2018, 19, 3950.	4.1	106
32	Combining statistical techniques to predict postsurgical risk of 1-year mortality for patients with colon cancer. Clinical Epidemiology, 2018, Volume 10, 235-251.	3.0	9
33	Predictors of one and two years' mortality in patients with colon cancer: A prospective cohort study. PLoS ONE, 2018, 13, e0199894.	2.5	6
34	Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study. BMC Cancer, 2018, 18, 54.	2.6	9
35	Cost-effectiveness analysis of laparoscopic versus open surgery in colon cancer. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 4912-4922.	2.4	9
36	Outcomes of open versus laparoscopic surgery in patients with colon cancer. European Journal of Surgical Oncology, 2018, 44, 1344-1353.	1.0	18

#	Article	IF	CITATIONS
37	High serum vascular endothelial growth factor C predicts better relapse-free survival in early clinically node-negative breast cancer. Oncotarget, 2018, 9, 28131-28140.	1.8	6
38	Clusterin inhibition mediates sensitivity to chemotherapy and radiotherapy in human cancer. Anti-Cancer Drugs, 2017, 28, 702-716.	1.4	28
39	Relationship Between Vitamin D Deficiency and the Components of Metabolic Syndrome in Patients with Morbid Obesity, Before and 1ÂYear After Laparoscopic Roux-en-Y Gastric Bypass or Sleeve Gastrectomy. Obesity Surgery, 2017, 27, 1222-1228.	2.1	15
40	Protein Kinase Targets in Breast Cancer. International Journal of Molecular Sciences, 2017, 18, 2543.	4.1	57
41	COPD is a clear risk factor for increased use of resources and adverse outcomes in patients undergoing intervention for colorectal cancer: a nationwide study in Spain. International Journal of COPD, 2017, Volume 12, 1233-1241.	2.3	20
42	Factors that influence treatment delay in patients with colorectal cancer. Oncotarget, 2017, 8, 36728-36742.	1.8	30
43	Colorectal cancer health services research study protocol: the CCR-CARESS observational prospective cohort project. BMC Cancer, 2016, 16, 435.	2.6	32
44	Appropriateness of diagnostic effort in hospital emergency room attention for episodes of <scp>COPD</scp> exacerbation. Journal of Evaluation in Clinical Practice, 2015, 21, 848-854.	1.8	6
45	Hypertension and the Fat-Soluble Vitamins A, D and E. International Journal of Environmental Research and Public Health, 2015, 12, 2793-2809.	2.6	8
46	Anthropometric Status and Nutritional Intake in Children (6–9 Years) in Valencia (Spain): The ANIVA Study. International Journal of Environmental Research and Public Health, 2015, 12, 16082-16095.	2.6	17
47	Correlation between serum levels of vascular endothelial growth factor-C and sentinel lymph node status in early breast cancer. Tumor Biology, 2015, 36, 9285-9293.	1.8	9
48	The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. Journal of Biosciences, 2015, 40, 441-463.	1.1	79
49	Downregulation of clusterin mediates sensitivity to protein kinase inhibitors in breast cancer cells. Anti-Cancer Drugs, 2015, 26, 85-89.	1.4	3
50	Queuing Theory to Decrease Waiting Times in Emergency Department. Archives of Trauma Research, 2014, 3, e10473.	0.9	1
51	Aggressiveness features and outcomes of true interval cancers. European Journal of Cancer Prevention, 2013, 22, 21-28.	1.3	39
52	The role and prognostic value of apoptosis in colorectal carcinoma. BMC Clinical Pathology, 2013, 13, 24.	1.8	27
53	Detection methods predict differences in biology and survival in breast cancer patients. BMC Cancer, 2012, 12, 604.	2.6	20
54	Immunohistochemical expression of cyclooxygenase-2 in patients with advanced cancer of the larynx who have undergone induction chemotherapy with the intention of preserving phonation. Clinical and Translational Oncology, 2012, 14, 682-688.	2.4	6

#	Article	IF	CITATIONS
55	Clinical Significance of Langerhans Cells in Squamous Cell Carcinoma of the Larynx. Journal of Oncology, 2012, 2012, 1-5.	1.3	13
56	The use of botulinum toxin in benign prostatic hyperplasia. Neurourology and Urodynamics, 2012, 31, 86-92.	1.5	17
57	Percutaneous Tibial Nerve Stimulation in Treatment of Overactive Bladder: When Should Retreatment Be Started?. Urology, 2011, 78, 1046-1050.	1.0	22
58	Role of Gene Methylation in Antitumor Immune Response: Implication for Tumor Progression. Cancers, 2011, 3, 1672-1690.	3.7	26
59	Clusterin expression is associated with decreased diseaseâ€free survival of patients with colorectal carcinomas. Histopathology, 2010, 56, 932-936.	2.9	22
60	Regulation of Clusterin Expression in Human Cancer via DNA Methylation. Tumor Biology, 2009, 30, 286-291.	1.8	14
61	Prognostic implications of emergency admission and delays in patients with breast cancer. Supportive Care in Cancer, 2009, 17, 595-599.	2.2	23
62	Expression of substance P and neurokininâ€1â€receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology, 2009, 54, 258-260.	2.9	46
63	The Role of Clusterin (CLU) in Malignant Transformation and Drug Resistance in Breast Carcinomas. Advances in Cancer Research, 2009, 105, 21-43.	5.0	21
64	Apoptosis in the Development and Treatment of Laryngeal Cancer: Role of p53, Bcl-2 and Clusterin. , 2009, , 237-249.		0
65	NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Investigational New Drugs, 2008, 26, 111-118.	2.6	73
66	Monitoring indicators of health care quality by means of a hospital register of tumours. Journal of Evaluation in Clinical Practice, 2008, 14, 1026-1030.	1.8	7
67	Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus. Molecular and Cellular Neurosciences, 2008, 39, 342-355.	2.2	108
68	Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity. Breast Cancer Research, 2007, 9, R86.	5.0	35
69	Expression of the Antiapoptotic Proteins Clusterin and Bcl-2 in Laryngeal Squamous Cell Carcinomas. Tumor Biology, 2006, 27, 195-200.	1.8	25
70	Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Human Pathology, 2003, 34, 1283-1289.	2.0	50
71	High frequency of HLA-B44 allelic losses in human solid tumors. Human Immunology, 2003, 64, 941-950.	2.4	26
72	Expression of bax and p53 Proteins in the Tumorigenesis and Progression of Breast Carcinomas. Tumor Biology, 2003, 24, 23-31.	1.8	6

#	Article	IF	CITATIONS
73	Quality assurance of point-of-care testing in the Costa del Sol Healthcare Area (Marbella, Spain). Clinica Chimica Acta, 2001, 307, 113-118.	1.1	9
74	<i>bcl-2</i> Expression and Apoptosis in Primary and Metastatic Breast Carcinomas. Tumor Biology, 2001, 22, 137-145.	1.8	31
75	Upregulation of glial clusterin in brains of patients with AIDs. Brain Research, 2001, 888, 297-301.	2.2	14
76	Overexpression of Clusterin in Human Breast Carcinoma. American Journal of Pathology, 2000, 157, 393-399.	3.8	228
77	Dexamethasone induces altered binding of regulatory factors to HLA class I enhancer sequence in MCF-7 breast tumour cell line. Cancer Immunology, Immunotherapy, 1998, 46, 194-200.	4.2	4
78	CD4+ cells in human ejaculates. Human Reproduction, 1995, 10, 2923-2927.	0.9	30
79	K-ras mutations (codon 12) are not involved in down-regulation of mhc class-i genes in colon carcinomas. International Journal of Cancer. 1990. 46, 426-431.	5.1	17